Do analysts rate BMK or AZN?

AstraZeneca has a consensus price target of £151.14, suggesting a potential upside of 28.74%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts clearly believe AstraZeneca is more favorable than Benchmark. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Benchmark 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 AstraZeneca 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has stronger valuation & earnings, BMK or AZN?

AstraZeneca has higher revenue and earnings than Benchmark. AstraZeneca is trading at a lower price-to-earnings ratio than Benchmark, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Benchmark £79.16M 1,189.43 -£39.55M £0.06 246,774.19 AstraZeneca £61.37B 2.97 £8.71B £668.00 17.58

Is BMK or AZN more profitable?

AstraZeneca has a net margin of 17.02% compared to Benchmark's net margin of -43.67%. AstraZeneca's return on equity of 21.68% beat Benchmark's return on equity. Company Net Margins Return on Equity Return on Assets Benchmark -43.67% -15.96% -1.07% AstraZeneca 17.02% 21.68% 7.68%

Which has preferable valuation and earnings, GSK or AZN?

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK £33.20B 2.14 £2.50B £117.80 15.03 AstraZeneca £61.37B 2.97 £8.71B £668.00 17.58

Is GSK or AZN more profitable?

AstraZeneca has a net margin of 17.02% compared to GSK's net margin of 14.52%. GSK's return on equity of 28.35% beat AstraZeneca's return on equity. Company Net Margins Return on Equity Return on Assets GSK 14.52% 28.35% 9.56% AstraZeneca 17.02% 21.68% 7.68%

Does the media favor GSK or AZN?

In the previous week, AstraZeneca had 3 more articles in the media than GSK. MarketBeat recorded 14 mentions for AstraZeneca and 11 mentions for GSK. GSK's average media sentiment score of 0.68 beat AstraZeneca's score of 0.21 indicating that GSK is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AstraZeneca 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Do analysts rate AZN or DPH?

AstraZeneca currently has a consensus price target of £151.14, suggesting a potential upside of 28.74%. Given AstraZeneca's stronger consensus rating and higher possible upside, research analysts clearly believe AstraZeneca is more favorable than Dechra Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AstraZeneca 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Dechra Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor HIK or AZN?

In the previous week, AstraZeneca had 9 more articles in the media than Hikma Pharmaceuticals. MarketBeat recorded 14 mentions for AstraZeneca and 5 mentions for Hikma Pharmaceuticals. AstraZeneca's average media sentiment score of 0.21 beat Hikma Pharmaceuticals' score of 0.05 indicating that AstraZeneca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hikma Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral AstraZeneca 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Do analysts rate INDV or AZN?

AstraZeneca has a consensus price target of £151.14, suggesting a potential upside of 28.74%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts clearly believe AstraZeneca is more favorable than Indivior. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indivior 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 AstraZeneca 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has better earnings and valuation, INDV or AZN?

AstraZeneca has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indivior £1.40B 1.38 -£2.36M -£1.21 N/A AstraZeneca £61.37B 2.97 £8.71B £668.00 17.58

Is INDV or AZN more profitable?

AstraZeneca has a net margin of 17.02% compared to Indivior's net margin of 11.44%. AstraZeneca's return on equity of 21.68% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets Indivior 11.44% -23.90% 2.37% AstraZeneca 17.02% 21.68% 7.68%

AstraZeneca (AZN) Competitors

£117.41 -17.51 (-0.15%)

As of 09/11/2026 12:15 PM Eastern

Compare

AZN vs. BMK, GSK, DPH, HIK, and INDV

Should you buy AstraZeneca stock or one of its competitors? AstraZeneca's main competitors and comparable companies include Benchmark (BMK), GSK (GSK), Dechra Pharmaceuticals (DPH), Hikma Pharmaceuticals (HIK), and Indivior (INDV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does AstraZeneca compare to Benchmark?

Benchmark (LON:BMK) and AstraZeneca (LON:AZN) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

AstraZeneca has a net margin of 17.02% compared to Benchmark's net margin of -43.67%. AstraZeneca's return on equity of 21.68% beat Benchmark's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Benchmark	-43.67%	-15.96%	-1.07%
AstraZeneca	17.02%	21.68%	7.68%

AstraZeneca has higher revenue and earnings than Benchmark. AstraZeneca is trading at a lower price-to-earnings ratio than Benchmark, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Benchmark	£79.16M	1,189.43	-£39.55M	£0.06	246,774.19
AstraZeneca	£61.37B	2.97	£8.71B	£668.00	17.58

13.3% of Benchmark shares are held by institutional investors. Comparatively, 67.8% of AstraZeneca shares are held by institutional investors. 63.7% of Benchmark shares are held by company insiders. Comparatively, 0.2% of AstraZeneca shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, AstraZeneca had 14 more articles in the media than Benchmark. MarketBeat recorded 14 mentions for AstraZeneca and 0 mentions for Benchmark. Benchmark's average media sentiment score of 0.67 beat AstraZeneca's score of 0.21 indicating that Benchmark is being referred to more favorably in the media.

Company	Overall Sentiment
Benchmark	Positive
AstraZeneca	Neutral

AstraZeneca has a consensus price target of £151.14, suggesting a potential upside of 28.74%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts clearly believe AstraZeneca is more favorable than Benchmark.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Benchmark	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Benchmark has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.205, meaning that its stock price is 80% less volatile than the broader market.

Summary

AstraZeneca beats Benchmark on 11 of the 16 factors compared between the two stocks.

How does AstraZeneca compare to GSK?

GSK (LON:GSK) and AstraZeneca (LON:AZN) are both large-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

In the previous week, AstraZeneca had 3 more articles in the media than GSK. MarketBeat recorded 14 mentions for AstraZeneca and 11 mentions for GSK. GSK's average media sentiment score of 0.68 beat AstraZeneca's score of 0.21 indicating that GSK is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AstraZeneca	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

GSK presently has a consensus target price of GBX 2,039.38, indicating a potential upside of 15.19%. AstraZeneca has a consensus target price of £151.14, indicating a potential upside of 28.74%. Given AstraZeneca's stronger consensus rating and higher probable upside, analysts clearly believe AstraZeneca is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

AstraZeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	£33.20B	2.14	£2.50B	£117.80	15.03
AstraZeneca	£61.37B	2.97	£8.71B	£668.00	17.58

56.9% of GSK shares are owned by institutional investors. Comparatively, 67.8% of AstraZeneca shares are owned by institutional investors. 0.2% of GSK shares are owned by insiders. Comparatively, 0.2% of AstraZeneca shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

GSK pays an annual dividend of GBX 67 per share and has a dividend yield of 3.8%. AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.7%. GSK pays out 56.9% of its earnings in the form of a dividend. AstraZeneca pays out 47.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

GSK has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.205, indicating that its stock price is 80% less volatile than the broader market.

AstraZeneca has a net margin of 17.02% compared to GSK's net margin of 14.52%. GSK's return on equity of 28.35% beat AstraZeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	14.52%	28.35%	9.56%
AstraZeneca	17.02%	21.68%	7.68%

Summary

AstraZeneca beats GSK on 12 of the 18 factors compared between the two stocks.

How does AstraZeneca compare to Dechra Pharmaceuticals?

AstraZeneca (LON:AZN) and Dechra Pharmaceuticals (LON:DPH) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.7%. Dechra Pharmaceuticals pays an annual dividend of GBX 45 per share. AstraZeneca pays out 47.4% of its earnings in the form of a dividend. Dechra Pharmaceuticals pays out -18,000.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

67.8% of AstraZeneca shares are owned by institutional investors. Comparatively, 105.5% of Dechra Pharmaceuticals shares are owned by institutional investors. 0.2% of AstraZeneca shares are owned by company insiders. Comparatively, 9.3% of Dechra Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

AstraZeneca has higher revenue and earnings than Dechra Pharmaceuticals. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AstraZeneca	£61.37B	2.97	£8.71B	£668.00	17.58
Dechra Pharmaceuticals	£761.50M	0.00	-£27.90M	-£0.25	N/A

In the previous week, AstraZeneca had 14 more articles in the media than Dechra Pharmaceuticals. MarketBeat recorded 14 mentions for AstraZeneca and 0 mentions for Dechra Pharmaceuticals. AstraZeneca's average media sentiment score of 0.21 beat Dechra Pharmaceuticals' score of 0.00 indicating that AstraZeneca is being referred to more favorably in the media.

Company	Overall Sentiment
AstraZeneca	Neutral
Dechra Pharmaceuticals	Neutral

AstraZeneca has a beta of 0.205, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, Dechra Pharmaceuticals has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

AstraZeneca has a net margin of 17.02% compared to Dechra Pharmaceuticals' net margin of -3.66%. AstraZeneca's return on equity of 21.68% beat Dechra Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AstraZeneca	17.02%	21.68%	7.68%
Dechra Pharmaceuticals	-3.66%	-3.92%	0.75%

AstraZeneca currently has a consensus price target of £151.14, suggesting a potential upside of 28.74%. Given AstraZeneca's stronger consensus rating and higher possible upside, research analysts clearly believe AstraZeneca is more favorable than Dechra Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Dechra Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

AstraZeneca beats Dechra Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does AstraZeneca compare to Hikma Pharmaceuticals?

Hikma Pharmaceuticals (LON:HIK) and AstraZeneca (LON:AZN) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Hikma Pharmaceuticals pays an annual dividend of GBX 82.48 per share and has a dividend yield of 5.4%. AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.7%. Hikma Pharmaceuticals pays out 46.9% of its earnings in the form of a dividend. AstraZeneca pays out 47.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Hikma Pharmaceuticals is clearly the better dividend stock, given its higher yield and lower payout ratio.

Hikma Pharmaceuticals presently has a consensus target price of GBX 2,085.83, indicating a potential upside of 36.24%. AstraZeneca has a consensus target price of £151.14, indicating a potential upside of 28.74%. Given Hikma Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Hikma Pharmaceuticals is more favorable than AstraZeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hikma Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Hikma Pharmaceuticals has a beta of 0.662, meaning that its share price is 34% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.205, meaning that its share price is 80% less volatile than the broader market.

AstraZeneca has a net margin of 17.02% compared to Hikma Pharmaceuticals' net margin of 11.31%. AstraZeneca's return on equity of 21.68% beat Hikma Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hikma Pharmaceuticals	11.31%	15.05%	9.40%
AstraZeneca	17.02%	21.68%	7.68%

AstraZeneca has higher revenue and earnings than Hikma Pharmaceuticals. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hikma Pharmaceuticals	£3.42B	0.93	£353.21M	£176.00	8.70
AstraZeneca	£61.37B	2.97	£8.71B	£668.00	17.58

63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.8% of AstraZeneca shares are owned by institutional investors. 22.3% of Hikma Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of AstraZeneca shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, AstraZeneca had 9 more articles in the media than Hikma Pharmaceuticals. MarketBeat recorded 14 mentions for AstraZeneca and 5 mentions for Hikma Pharmaceuticals. AstraZeneca's average media sentiment score of 0.21 beat Hikma Pharmaceuticals' score of 0.05 indicating that AstraZeneca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hikma Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
AstraZeneca	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

AstraZeneca beats Hikma Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does AstraZeneca compare to Indivior?

Indivior (LON:INDV) and AstraZeneca (LON:AZN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Indivior has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, AstraZeneca has a beta of 0.205, suggesting that its stock price is 80% less volatile than the broader market.

AstraZeneca has a net margin of 17.02% compared to Indivior's net margin of 11.44%. AstraZeneca's return on equity of 21.68% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	11.44%	-23.90%	2.37%
AstraZeneca	17.02%	21.68%	7.68%

AstraZeneca has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	£1.40B	1.38	-£2.36M	-£1.21	N/A
AstraZeneca	£61.37B	2.97	£8.71B	£668.00	17.58

In the previous week, AstraZeneca had 14 more articles in the media than Indivior. MarketBeat recorded 14 mentions for AstraZeneca and 0 mentions for Indivior. Indivior's average media sentiment score of 0.64 beat AstraZeneca's score of 0.21 indicating that Indivior is being referred to more favorably in the media.

Company	Overall Sentiment
Indivior	Positive
AstraZeneca	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
AstraZeneca	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. AstraZeneca pays an annual dividend of GBX 316.71 per share and has a dividend yield of 2.7%. Indivior pays out -1,243.7% of its earnings in the form of a dividend. AstraZeneca pays out 47.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

86.0% of Indivior shares are owned by institutional investors. Comparatively, 67.8% of AstraZeneca shares are owned by institutional investors. 3.4% of Indivior shares are owned by insiders. Comparatively, 0.2% of AstraZeneca shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

AstraZeneca beats Indivior on 14 of the 18 factors compared between the two stocks.

Get AstraZeneca News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AZN vs. The Competition

Export

Metric	AstraZeneca	Pharmaceuticals Industry	Healthcare Sector	LON Exchange
Market Cap	£182.08B	£12.46B	£7.16B	£2.87B
Dividend Yield	1.98%	2.62%	2.56%	6.23%
P/E Ratio	17.58	799.74	274.10	366.83
Price / Sales	2.97	763.35	656.00	83,599.70
Price / Cash	38.89	89.25	77.04	27.89
Price / Book	4.46	10.39	10.33	6.33
Net Income	£8.71B	£2.85B	£3.50B	£5.89B
7 Day Performance	-2.21%	-3.70%	-3.35%	-0.69%
1 Month Performance	0.33%	0.78%	-0.43%	0.18%
1 Year Performance	-0.45%	3.48%	19.21%	20.03%

AstraZeneca Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AZN AstraZeneca	4.5286 of 5 stars	£117.40 -0.1%	£151.14 +28.7%	-1.8%	£182.08B	£61.37B	17.58	96,100	Positive News High Trading Volume
BMK Benchmark	N/A	£153 -0.6%	N/A	+0.0%	£94.15B	£79.16M	246,774.19	823
GSK GSK	3.5792 of 5 stars	GBX 1,770.50 -0.3%	GBX 2,039.38 +15.2%	+16.7%	£70.94B	£33.20B	15.03	66,841	Trending News Analyst Forecast High Trading Volume
DPH Dechra Pharmaceuticals	N/A	N/A	N/A	N/A	£4.40B	£761.50M	N/A	2,457
HIK Hikma Pharmaceuticals	4.6769 of 5 stars	GBX 1,531 +2.2%	GBX 2,085.83 +36.2%	-7.8%	£3.17B	£3.42B	8.70	9,100	News Coverage High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:AZN) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AstraZeneca (AZN) Competitors

AZN vs. BMK, GSK, DPH, HIK, and INDV

How does AstraZeneca compare to Benchmark?

Summary

How does AstraZeneca compare to GSK?

Summary

How does AstraZeneca compare to Dechra Pharmaceuticals?

Summary

How does AstraZeneca compare to Hikma Pharmaceuticals?

Summary

How does AstraZeneca compare to Indivior?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZN vs. The Competition

AstraZeneca Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AstraZeneca (AZN) Competitors

AZN vs. BMK, GSK, DPH, HIK, and INDV

How does AstraZeneca compare to Benchmark?

Is BMK or AZN more profitable?

Which has stronger valuation & earnings, BMK or AZN?

Do institutionals and insiders hold more shares of BMK or AZN?

Does the media prefer BMK or AZN?

Do analysts rate BMK or AZN?

Which has more volatility and risk, BMK or AZN?

Summary

How does AstraZeneca compare to GSK?

Does the media favor GSK or AZN?

Do analysts prefer GSK or AZN?

Which has preferable valuation and earnings, GSK or AZN?

Do institutionals and insiders hold more shares of GSK or AZN?

Is GSK or AZN a better dividend stock?

Which has more volatility & risk, GSK or AZN?

Is GSK or AZN more profitable?

Summary

How does AstraZeneca compare to Dechra Pharmaceuticals?

Is AZN or DPH a better dividend stock?

Do institutionals and insiders hold more shares of AZN or DPH?

Which has preferable earnings & valuation, AZN or DPH?

Does the media refer more to AZN or DPH?

Which has more volatility and risk, AZN or DPH?

Is AZN or DPH more profitable?

Do analysts rate AZN or DPH?

Summary

How does AstraZeneca compare to Hikma Pharmaceuticals?

Is HIK or AZN a better dividend stock?

Do analysts prefer HIK or AZN?

Which has more volatility and risk, HIK or AZN?

Is HIK or AZN more profitable?

Which has better earnings and valuation, HIK or AZN?

Do insiders & institutionals believe in HIK or AZN?

Does the media favor HIK or AZN?

Summary

How does AstraZeneca compare to Indivior?

Which has more risk & volatility, INDV or AZN?

Is INDV or AZN more profitable?

Which has better earnings and valuation, INDV or AZN?

Does the media prefer INDV or AZN?

Do analysts rate INDV or AZN?

Is INDV or AZN a better dividend stock?

Do institutionals & insiders hold more shares of INDV or AZN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AZN vs. The Competition

AstraZeneca Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools